CRVS Stock Annual Balance Sheet. Download in Excel
Corvus Pharmaceuticals Inc.
CRVS 
NSD
Sector: Healthcare
Industry: Biotechnology
8.94
USD
0.70
(8.50%)
Previous close: 8.24 Open: 8.24 Bid: 8.5 Ask: 8.98
52 week range
1.30 10.00
Mkt Cap: 540 M Avg Vol (90 Days): 721,352
Last updated: Friday 22nd November 2024
Financials
CRVS Balance Sheet
Annual
| Invalid date | Dec-16 | Dec-17 | Dec-18 | Dec-19 | Dec-20 | Dec-21 | Dec-22 | Dec-23 | |
|---|---|---|---|---|---|---|---|---|---|
| Accounts payable | 2 M | 3 M | 2 M | 2 M | 3 M | 2 M | 2 M | 2 M | |
| Accounts receivable | 588000.0 | 26000.0 | |||||||
| Accrued expenses | 2 M | 3 M | 2 M | 2 M | 3 M | 2 M | 2 M | 2 M | |
| AccruedInterestReceivable | 337000.0 | 329000.0 | 86000.0 | 32000.0 | 45000.0 | 37000.0 | |||
| Accumulated depreciation & depletion | -2 M | -3 M | -4 M | -4 M | -5 M | -5 M | |||
| Additional paid in capital | 201 M | 208 M | 281 M | 288 M | 295 M | 362 M | 364 M | 374 M | |
| Cash and equivalents | 5 M | 45 M | 39 M | 5 M | 16 M | 63 M | 13 M | 13 M | |
| CashCashEquivalentsAndShortTermInvestments | 135 M | 90 M | 115 M | 78 M | 44 M | 69 M | 42 M | 27 M | |
| CashEquivalents | 5 M | 45 M | 78 M | ||||||
| Common par | 2000.0 | 2000.0 | 3000.0 | 3000.0 | 3000.0 | 5000.0 | 5000.0 | 5000.0 | |
| Common stock equity | 133 M | 85 M | 110 M | 71 M | 72 M | 97 M | 56 M | 39 M | |
| CommonStock | 2000.0 | 2000.0 | 3000.0 | 3000.0 | 3000.0 | 5000.0 | 5000.0 | 5000.0 | |
| CurrentCapitalLeaseObligation | 1 M | 878000.0 | 1 M | 1 M | 1 M | 1 M | |||
| Float term debt | 1 M | 3 M | 1 M | ||||||
| Gross fixed assets (Plant Property & Equipment) | 3 M | 3 M | 5 M | 7 M | 6 M | 8 M | 7 M | 6 M | |
| Invested capital | 133 M | 85 M | 110 M | 71 M | 73 M | 100 M | 57 M | 39 M | |
| LongTermCapitalLeaseObligation | 2 M | 1 M | 3 M | 1 M | |||||
| LongTermDebtAndCapitalLeaseObligation | 2 M | 1 M | 3 M | 1 M | |||||
| Net fixed assets (net PP&E) | 3 M | 3 M | 2 M | 4 M | 3 M | 4 M | 3 M | 1 M | |
| NonCurrentDeferredTaxesAssets | 41 M | 55 M | 56 M | 68 M | 77 M | 83 M | |||
| Other current assets | 2 M | 2 M | 12 M | 13 M | 13 M | 13 M | |||
| Other equity adjustments | -39000.0 | -41000.0 | -34000.0 | 29000.0 | |||||
| Other fixed assets | 4 M | 3 M | 4 M | 3 M | 1 M | ||||
| Other non-current assets | 869000.0 | 869000.0 | 463000.0 | 513000.0 | 414000.0 | 236000.0 | 129000.0 | 89000.0 | |
| Other non-current liabilities | 1 M | 971000.0 | 869000.0 | ||||||
| Other receivable | 507000.0 | 588000.0 | |||||||
| OtherCurrentLiabilities | 8 M | 7 M | 8 M | 4 M | |||||
| Payables | 2 M | 3 M | 2 M | 2 M | 3 M | 2 M | 2 M | 2 M | |
| Preferred securities of subsidiary trust | 10 M | 10 M | 10 M | ||||||
| PreferredStock | 10 M | 10 M | 10 M | ||||||
| Prepaid expenses | 1 M | 1 M | 992000.0 | 1 M | 1 M | 1 M | 773000.0 | 781000.0 | |
| Retained earnings | -68 M | -124 M | -170 M | -217 M | -223 M | -265 M | -308 M | -336 M | |
| Total assets | 140 M | 95 M | 118 M | 84 M | 86 M | 109 M | 68 M | 46 M | |
| Total current assets | 136 M | 91 M | 116 M | 79 M | 45 M | 71 M | 44 M | 28 M | |
| Total current liabilities | 6 M | 9 M | 7 M | 3 M | 12 M | 10 M | 11 M | 7 M | |
| Total equity | 133 M | 85 M | 110 M | 71 M | 72 M | 97 M | 56 M | 39 M | |
| Total liabilities | 7 M | 10 M | 8 M | 6 M | 13 M | 12 M | 12 M | 7 M | |
| Total non-current assets | 4 M | 4 M | 3 M | 4 M | 40 M | 38 M | 25 M | 18 M | |
| Total non-current liabilities | 1 M | 971000.0 | 869000.0 | 2 M | 1 M | 3 M | 1 M | ||
| TotalEquityGrossMinority | 133 M | 85 M | 110 M | 71 M | 72 M | 97 M | 56 M | 39 M | |
| TotalEquityGrossMinorityInterest | 133 M | 85 M | 110 M | 71 M | 72 M | 97 M | 56 M | 39 M | |
| TotalLiabilitiesAndTotalEquityGrossMinorityInterest | 140 M | 95 M | 118 M | 84 M | 86 M | 109 M | 68 M | 46 M | |
| TotalNonCurrentLiabilitiesNetMinorityInteres | 1 M | 971000.0 | 869000.0 | 2 M | 1 M | 3 M | 1 M | ||
| Working capital | 130 M | 82 M | 109 M | 76 M | 33 M | 62 M | 33 M | 21 M | |
| debtc | 878000.0 | 1 M | 1 M | 1 M | 1 M | ||||
| ltinv | 37 M | 34 M | 22 M | 16 M |
Call: 1-877-778-8358 
Welcome! I'm Ankur, the founder and CEO of MarketXLS. With more than ten years of experience, I have assisted over 2,500 customers in developing personalized investment research strategies and monitoring systems using Excel.
I invite you to book a demo with me or my team to save time, enhance your investment research, and streamline your workflows.
I invite you to book a demo with me or my team to save time, enhance your investment research, and streamline your workflows.
Implement “your own” investment strategies in Excel with thousands of MarketXLS functions and templates.
MarketXLS is a complete Excel stock solution
I have used lots of stock and option information services. This is the only one which gives me what I need inside Excel
MarketXLS is a data junkie’s dream. It gives me the flexibility to mine for hidden treasures.
I like to access historical closing prices on a particular date. That makes tracking performance easy.